Lilly is warning the public that tirzepatide mixed with B12 is creating an impurity with “unknown effects” in humans.

Though it’s hard to say exactly what the future holds for mass GLP-1 compounding, the pressure is mounting from multiple angles in the U.S. | Eli Lilly—which has already staged multiple efforts in ...

WASHINGTON, March 12 (Reuters) - Compounded weight-loss drugs that contain vitamin B12 and the main ingredient in Eli Lilly's Zepbound could present health risks to consumers due to a previously ...

Drugmaker called on FDA to initiate recall ...

Eli Lilly and Co LLY on Thursday issued a public warning about potential safety risks linked to compounded tirzepatide ...

Testing identified significant impurity formation when tirzepatide is compounded with B12 variants, suggesting chemical incompatibility that is not evaluated under FDA review pathways. Uncertainty ...